Apigenin inhibits endothelial-cell proliferation in G2/M phase whereas it stimulates smooth-muscle cells by inhibiting P21 and P27 expression

✍ Scribed by Véronique Trochon; Emmanuel Blot; Florence Cymbalista; Carsten Engelmann; Ruo-Ping Tang; Annick Thomaïdis; Marc Vasse; Jeannette Soria; He Lu; Claudine Soria

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: French
• Weight: 100 KB
• Volume: 85
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/(sici)1097-0215(20000301)85:5<691::aid-ijc15>3.0.co;2-q

✦ Synopsis

Apigenin is a plant flavonoid that is thought to play a role in the prevention of carcinogenesis. However, its mechanism of action has not yet been elucidated. Because of the importance of angiogenesis in tumor growth, we investigated the effect of apigenin on endothelial and smooth-muscle cells in an in vitro model. Apigenin markedly inhibited the proliferation, and, to a lesser degree, the migration of endothelial cells, and capillary formation in vitro, independently of its inhibition of hyaluronidase activity. In contrast, it strongly stimulated vascular smooth-muscle-cell proliferation. The molecular mechanisms of apigenin activity were analyzed in these 2 types of cells. Our results show that apigenin inhibits endothelial-cell proliferation by blocking the cells in the G(2)/M phase as a result of the accumulation of the hyperphosphorylated form of the retinoblastoma protein. Apigenin stimulation of smooth-muscle cells was attributed to the reduced expression of 2 cyclin-dependent kinase inhibitors, p21 and p27, which negatively regulate the G(1)-phase cyclin-dependent kinase.